Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01616199
Recruitment Status : Terminated (slow accrual)
First Posted : June 11, 2012
Last Update Posted : May 16, 2018
Sponsor:
Information provided by (Responsible Party):
Seattle Genetics, Inc. ( Cascadian Therapeutics Inc. )

Tracking Information
First Submitted Date  ICMJE June 6, 2012
First Posted Date  ICMJE June 11, 2012
Last Update Posted Date May 16, 2018
Study Start Date  ICMJE August 2012
Actual Primary Completion Date December 2014   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 7, 2012)
  • Incidence and severity of adverse events (phase 1) [ Time Frame: 28 days ]
  • Progression-free survival (PFS) (phase 2) [ Time Frame: 56 days ]
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT01616199 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: June 7, 2012)
  • Plasma concentrations of PX-866 and metabolites (phase 1) [ Time Frame: 44 days ]
  • Objective Response Rate (ORR)(phase 2) [ Time Frame: 56 days ]
  • Disease Control Rate (DCR)(phase 2) [ Time Frame: 56 Days ]
  • Plasma concentrations of vemurafenib (phase 1) [ Time Frame: 44 days ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
Official Title  ICMJE Phase 1/2 Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) in Patients With BRAF-mutant Cancer Including Advanced Melanoma
Brief Summary

The purpose of the phase 1 portion of the study is to determine the maximally tolerated dose (MTD) or recommended dose (RD) and the safety/tolerability of PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer.

The purpose of the phase 2 portion of the study is to compare progression free survival (PFS), antitumor activity (response rate), disease control rate (DCR), and the safety and tolerability of PX-866 in combination with vemurafenib vs. vemurafenib alone in patients with advanced BRAF-mutant melanoma at the doses recommended from Phase 1.

Detailed Description

This is a Phase 1 / 2 open-label study of PX-866 given in combination with vemurafenib to patients with BRAF-mutant cancer, including advanced melanoma.

Phase 1 will use a 3+3 dose escalation design to evaluate up to three dose levels of PX-866 in combination with up to two dose levels of vemurafenib in order to identify the maximal tolerated dose/recommended dose (MTD/RD) of both PX-866 and vemurafenib to be used in Phase 2. Vemurafenib will be administered orally twice per day on days 1-28 of all cycles except cycle 1, where vemurafenib will be administered on days 9-28 to allow for PK assessments). PX-866 will be administered once per day on days 1-28 of each cycle.

Phase 2 will evaluate the antitumor activity and safety of PX-866 given to patients randomized 2:1 to receive combination with vemurafenib at the doses recommended from Phase 1 compared with vemurafenib alone administered at the approved dose orally BID. All treatments will be administered on a 28-day cycle.

Patients randomized to receive single-agent vemurafenib may cross-over to receive the combination treatment at the time of progression. Patients will be evaluated for progression approximately every 8 weeks for the initial 24 weeks and every 12 weeks thereafter. All patients with stable disease (SD) or better, will receive repeat cycles until disease progression (PD), unacceptable toxicity, or withdrawal of consent.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Advanced BRAF-mutant Cancers
Intervention  ICMJE
  • Drug: PX-866

    Phase 1 dose escalation: PX-866 in combination administered orally every day in 28-day cycles until progression or unacceptable toxicity.

    Phase 2 combination: PX-866 and vemurafenib administered every day in 28 day cycles until progression or unacceptable toxicity.

    Phase 2 single-agent: vemurafenib administered orally at labeled dose every day in 28 day cycles until progression or unacceptable toxicity.

    Other Name: PI-3K inhibitor
  • Drug: vemurafenib
    vemurafenib is a B-Raf enzyme inhibitor
    Other Name: Zelboraf
Study Arms  ICMJE
  • Experimental: Phase 1 Dose Escalation of PX-866 + vemurafenib
    PX-866 given with vemurafenib
    Interventions:
    • Drug: PX-866
    • Drug: vemurafenib
  • Experimental: Phase 2 Combination PX-866 + vemurafenib
    PX-866 given with vemurafenib
    Interventions:
    • Drug: PX-866
    • Drug: vemurafenib
  • Active Comparator: Phase 2 Single-agent vemurafenib
    vemurafenib given as a single agent
    Intervention: Drug: vemurafenib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: April 30, 2015)
24
Original Estimated Enrollment  ICMJE
 (submitted: June 7, 2012)
146
Actual Study Completion Date  ICMJE March 2015
Actual Primary Completion Date December 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • ≥ 18 years at time of consent
  • If a sexually active male or a sexually active female of child-bearing potential, agrees to use a highly effective form of contraception (including birth control pills, barrier device, or intrauterine device)from the time of consent 90 days following the last dose of study drug
  • If female of child-bearing potential, negative pregnancy test
  • For Phase 1: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive (V600E or V600K) for which there is no remaining standard therapy with curative potential. Patients must have disease sites amenable to biopsy. For Phase 2: must have histologically or cytologically-confirmed BRAF mutation-positive (V600E or V600K) advanced (defined as unresectable Stage IIIC or IV) melanoma that has not been treated with a selective BRAF inhibitor
  • For Phase 1: must have measurable or non-measurable disease. For Phase 2: must have measurable disease per RECIST 1.1
  • For Phase 1: no restriction on number of prior therapy regimens. For Phase 2: the following restrictions on prior therapy apply: 1) must not have been treated with a selective BRAF inhibitor and must not have had more than 2 prior treatment regimens for advanced metastatic disease; 2) must have completed prior cytotoxic chemotherapy a minimum of 4 weeks prior to starting PX-866 and/or vemurafenib (except for BCNU and/or mitomycin C, which must have been completed a minimum of 6 weeks prior to starting therapy). Prior biologic therapy and localized radiation therapy must have been completed a minimum of 2 weeks prior to starting therapy.
  • All toxicities related to prior cancer therapies other than alopecia must have resolved to Grade 1 or less
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • In the opinion of the clinical investigator, life expectancy > 3 months
  • Adequate hematologic function
  • Adequate hepatic function
  • Serum creatinine < 2.0 mg/dL
  • Adequate cardiac function
  • Corrected QTc must be <480 milliseconds

Exclusion Criteria:

  • May not be receiving any other investigational agents
  • Active central nervous system (CNS) metastases are excluded. Patients with a history of CNS metastasis, who have been treated prior to enrollment, must be stable for eight weeks after completion of treatment. These patients must have undergone appropriate imaging studies and currently be on a stable, lowest possible dose of steroids
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to PX-866 or vemurafenib
  • Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Uncorrectable electrolyte abnormalities or long QT syndrome
  • Poorly controlled diabetes mellitus
  • Pregnant, breastfeeding, or planning to become pregnant
  • Known to be human immunodeficiency virus (HIV)-positive
  • Inability to swallow pills
  • Previous treatment with a phosphatidylinositol-3-kinase (PI-3K) inhibitor
  • Any other significant medical or psychiatric condition that in the opinion of the investigator renders the patient inadequate for participation
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01616199
Other Study ID Numbers  ICMJE PX-866-007
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Seattle Genetics, Inc. ( Cascadian Therapeutics Inc. )
Study Sponsor  ICMJE Cascadian Therapeutics Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Seattle Genetics, Inc.
Verification Date July 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP